Miniaturized pre-clinical cancer models as research and diagnostic tools

Advanced Drug Delivery Reviews

Volumn 69-70, Issue , 2014, Pages 52-66

  Håkanson, Maria ^a   Cukierman, Edna ^b   Charnley, Mirren ^c  

^a CSEM   (Switzerland)

^b FOX CHASE CANCER CENTER   (United States)

^c SWINBURNE UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

Body on a chip; Cancer models; Cell adhesion mediated drug resistance; Cell culturing devices; Combinatorial screening platforms; Extracellular matrix; Microfabricated model systems; Microfluidics; Pre clinical drug assessment; Tumor microenvironment

Indexed keywords

CELL ADHESION; CLINICAL RESEARCH; DIAGNOSIS; MICROFABRICATION; MICROFLUIDICS; PLASTICITY;

BODY-ON-A-CHIP; CANCER MODELS; CELL CULTURING; COMBINATORIAL SCREENINGS; DRUG RESISTANCE; EXTRACELLULAR MATRICES; MODEL SYSTEM; PRE-CLINICAL; TUMOR MICROENVIRONMENT;

DISEASES;

ANTINEOPLASTIC AGENT; REAGENT;

ANALYTIC METHOD; AUTOMATION; CANCER CELL; CANCER DIAGNOSIS; CANCER METABOLISM; CANCER MODEL; CANCER RESEARCH; CELL ADHESION; CELL CULTURE; CELL INTERACTION; DRUG DEVELOPMENT; DRUG RESEARCH; DRUG RESISTANCE; DRUG UPTAKE; ENVIRONMENTAL FACTOR; EXTRACELLULAR MATRIX; HUMAN; INTERMETHOD COMPARISON; METABOLISM; MICROTECHNOLOGY; NONHUMAN; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; REVIEW; STANDARD; TREATMENT RESPONSE; TUMOR INVASION; TUMOR MICROENVIRONMENT; ANIMAL; BIOLOGICAL MODEL; DRUG EFFECTS; DRUG SCREENING; ELECTRONICS; MEDICAL RESEARCH; MICROFLUIDIC ANALYSIS; NEOPLASMS; PHYSIOLOGY; PROCEDURES; TRENDS;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOMEDICAL RESEARCH; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; HUMANS; MICROFLUIDIC ANALYTICAL TECHNIQUES; MINIATURIZATION; MODELS, BIOLOGICAL; NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84899993200     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2013.11.010     Document Type: Review

References (245)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J. Clin. 2013, 63:11-30.
2. Maziasz T., Kadambi V.J., Silverman L., Fedyk E., Alden C.L. Predictive toxicology approaches for small molecule oncology drugs. Toxicol. Pathol. 2010, 38:148-164.
3. Kola I., Landis J. Can the pharmaceutical industry reduce attrition rates?. Nat. Rev. Drug Discov. 2004, 3:711-715.
4. Kamb A., Wee S., Lengauer C. Why is cancer drug discovery so difficult?. Nat. Rev. Drug Discov. 2007, 6:115-120.
5. Teicher B.A. Acute and chronic in vivo therapeutic resistance. Biochem. Pharmacol. 2009, 77:1665-1673.
6. Cukierman E., Bassi D.E. The mesenchymal tumor microenvironment A drug-resistant niche. Cell Adhes. Migr. 2012, 6:285-296.
7. Gillet J.-P., Varma S., Gottesman M.M. The clinical relevance of cancer cell lines. J. Natl. Cancer Inst. 2013, 105:452-458.
8. Desgrosellier J.S., Cheresh D.A. Integrins in cancer: biological implications and therapeutic opportunities. Nat. Rev. Cancer 2010, 10:9-22.
9. Murphy E., Majeti B., Barnes L., Makale M., Weis S., Lutu-Fuga K., Wrasidlo W., Cheresh D.A. Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:9343-9348.
10. Onishi T., Hayashi N., Theriault R.L., Hortobagyi G.N., Ueno N.T. Future directions of bone-targeted therapy for metastatic breast cancer. Nat. Rev. Clin. Oncol. 2010, 7:641-651.
11. Paszek M., Zahir N., Johnson K., Lakins J., Rozenberg G., Gefen A., Reinhart-King C., Margulies S., Dembo M., Boettiger D., Hammer D.A., Weaver V.M. Tensional homeostasis and the malignant phenotype. Cancer Cell 2005, 8:241-254.
12. Castelló-Cros R., Khan D.R., Simons J., Valianou M., Cukierman E. Staged stromal extracellular 3D matrices differentially regulate breast cancer cell responses through PI3K and beta1-integrins. BMC Cancer 2009, 9:94.
13. Goetz J.G., Minguet S., Navarro-Lerida I., R J.J.L., Samaniego R., Calvo E., Tello M., Osteso-Ibanez T., Pellinen T., Echarri A., Cerezo A., Klein-Szanto A.J., Garcia R., Keely P.J., Sánchez-Mateos P., Cukierman E., Pozo M.A.D. Biomechanical remodeling of the microenvironment by stromal caveolin-1 favors tumor invasion and metastasis. Cell 2011, 146:148-163.
14. Park C.C., Zhang H.J., Yao E.S., Park C.J., Bissell M.J. β1 integrin inhibition dramatically enhances radiotherapy efficacy in human breast cancer xenografts. Cancer Res. 2008, 68:4398-4405.
15. Meads M., Gatenby R., Dalton W. Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat. Rev. Cancer 2009, 9:665-674.
16. Franco O.E., Shaw A.K., Strand D.W., Hayward S.W. Cancer associated fibroblasts in cancer pathogenesis. Semin. Cell Dev. Biol. 2010, 21:33-39.
17. Eberle K.E., Sansing H.A., Szaniszlo P., Resto V.A., Berrier A.L. Carcinoma matrix controls resistance to cisplatin through talin regulation of NF-kB. PLoS ONE 2011, 6:e21496.
18. Flach E.H., Rebecca V.W., Herlyn M., Smalley K.S., Anderson A.R. Fibroblasts contribute to melanoma tumor growth and drug resistance. Mol. Pharm. 2011, 8:2039-2049.
19. Straussman R., Morikawa T., Shee K., Barzily-Rokni M., Qian Z.R., Du J., Davis A., Mongare M.M., Gould J., Frederick D.T., Cooper Z.A., Chapman P.B., Solit D.B., Ribas A., Lo R.S., Flaherty K.T., Ogino S., Wargo J.A., Golub T.R. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012, 487:500-504.
20. Cukierman E., Khan D.R. The benefits and challenges associated with the use of drug delivery systems in cancer therapy. Biochem. Pharmacol. 2010, 80:762-770.
21. Tunggal J.K., Cowan D.S., Shaikh H., Tannock I.F. Penetration of anticancer drugs through solid tissue: a factor that limits the effectiveness of chemotherapy for solid tumors. Clin. Cancer Res. 1999, 5:1583-1586.
22. Feig C., Gopinathan A., Neesse A., Chan D.S., Cook N., Tuveson D.A. The pancreas cancer microenvironment. Clin. Cancer Res. 2012, 18:4266-4276.
23. Kadaba R., Birke H., Wang J., Hooper S., Andl C.D., Maggio F.D., Soylu E., Ghallab M., Bor D., Froeling F.E., Bhattacharya S., Rustgi A.K., Sahai E., Chelala C., Sasieni P., Kocher H.M. Imbalance of desmoplastic stromal cell numbers drives aggressive cancer processes. J. Pathol. 2013, 230:107-117.
24. Friedrich J., Seidel C., Ebner R., Kunz-Schughart L. Spheroid-based drug screen: considerations and practical approach. Nat. Protoc. 2009, 4:309-324.
25. Kostadinova R., Boess F., Applegate D., Suter L., Weiser T., Singer T., Naughton B., Roth A. A long-term three dimensional liver co-culture system for improved prediction of clinically relevant drug-induced hepatotoxicity. Toxicol. Appl. Pharmacol. 2013, 268:1-16.
26. Bhadriraju K., Chen C.S. Engineering cellular microenvironments to improve cell-based drug testing. Drug Discov. Today 2002, 7:612-620.
27. Friedrich J., Ebner R., Kunz-Schughart L. Experimental anti-tumor therapy in 3-D: spheroids-old hat or new challenge?. Int. J. Radiat. Biol. 2007, 83:849-871.
28. Cukierman E., Pankov R., Stevens D.R., Yamada K.M. Taking cell-matrix adhesions to the third dimension. Science 2001, 294:1708-1712.
29. Trappmann B., Gautrot J.E., Connelly J.T., Strange D.G.T., Li Y., Oyen M.L., Cohen Stuart M.A., Boehm H., Li B., Vogel V., Spatz J.P., Watt F.M., Huck W.T.S. Extracellular-matrix tethering regulates stem-cell fate. Nat. Mater. 2012, 11:642-649.
30. Discher D.E., Mooney D.J., Zandstra P.W. Growth factors, matrices, and forces combine and control stem cells. Science 2009, 324:1673-1677.
31. Debnath J., Muthuswamy S., Brugge J. Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 2003, 30:256-268.
32. Yamada K.M., Cukierman E. Modeling tissue morphogenesis and cancer in 3D. Cell 2007, 130:601-610.
33. Serebriiskii I., Castelló-Cros R., Lamb A., Golemis E., Cukierman E. Fibroblast-derived 3D matrix differentially regulates the growth and drug-responsiveness of human cancer cells. Matrix Biol. 2008, 27:573-585.
34. Lee H.-O., Mullins S.R., Franco-Barraza J., Valianou M., Cukierman E., Cheng J.D. FAP-overexpressing fibroblasts produce an extracellular matrix that enhances invasive velocity and directionality of pancreatic cancer cells. BMC Cancer 2011, 11:245.
35. Petrie R.J., Yamada K.M. At the leading edge of three-dimensional cell migration. J. Cell Sci. 2012, 125:5917-5926.
36. Nelson C., Bissell M. Modeling dynamic reciprocity: engineering three-dimensional culture models of breast architecture, function, and neoplastic transformation. Semin. Cancer Biol. 2005, 15:342-352.
37. Stein W. Mining Databases to find the Genes that Determine the Intractability of Human Tumors, in: CHI's Tissue Models for Therapeutics, Boston, MA, USA 2005.
38. Cree I., Glaysher S., Harvey A. Efficacy of anti-cancer agents in cell lines versus human primary tumour tissue. Curr. Opin. Pharmacol. 2010, 4:375-379.
39. Goldbard S. Bringing primary cells to mainstream drug development and drug testing. Curr. Opin. Drug Discovery Dev. 2006, 9:110-116.
40. Trusheim M.R., Berndt E.R., Douglas F.L. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat. Rev. Drug Discov. 2007, 6:287-293.
41. Ganser A., Roth G., van Galen J.C., Hilderink J., Wammes J.J.G., Müller I., van Leeuwen F.N., Wiesmüller K.-H., Brock R. Diffusion-driven device for a high-resolution dose-response profiling of combination chemotherapy. Anal. Chem. 2009, 81:5233-5240.
42. Bhatia S.N., Balis U.J., Yarmush M.L., Toner M. Effect of cell-cell interactions in preservation of cellular phenotype: cocultivation of hepatocytes and nonparenchymal cells. FASEB J. 1999, 13:1883-1900.
43. Pavlovich A.L., Manivannan S., Nelson C.M. Adipose stroma induces branching morphogenesis of engineered epithelial tubules. Tissue Eng. Part A 2010, 16:3719-3726.
44. Xu F., Celli J., Rizvi I., Moon S., Hasan T., Demirci U. A three-dimensional in vitro ovarian cancer coculture model using a high-throughput cell patterning platform. Biotechnol. J. 2011, 6:204-212.
45. Kalabis J., Wong G.S., Vega M.E., Natsuizaka M., Robertson E.S., Herlyn M., Nakagawa H., Rustgi A.K. Isolation and characterization of mouse and human esophageal epithelial cells in 3D organotypic culture. Nat. Protoc. 2012, 7:235-246.
46. Lee K.Y., Mooney D.J. Alginate: properties and biomedical applications. Prog. Polym. Sci. 2012, 37:106-126.
47. Håkanson M., Textor M., Charnley M. Engineered 3D environments to elucidate the effect of environmental parameters on drug response in cancer. Integr. Biol. 2011, 1-8.
48. Lin L., Perets A., Har-el Y.-e., Varma D., Li M., Lazarovici P., Woerdeman D.L., Lelkes P.I. Alimentary 'green' Proteins as Electrospun Scaffolds for Skin Regenerative Engineering. J. Tissue Eng. Regen. Med. 2013, (In press). 10.1002/term.1493.
49. Lo A., Mori H., Mott J., Bissell M. Constructing three-dimensional models to study mammary gland branching morphogenesis and functional differentiation. J. Mammary Gland Biol. Neoplasia 2012, 17:103-110.
50. Gupta V., Bassi D.E., Simons J.D., Devarajan K., Al-Saleem T., Uzzo R.G., Cukierman E. Elevated expression of stromal palladin predicts poor clinical outcome in renal cell carcinoma. PLoS ONE 2011, 6:e21494.
51. Charnley M., Kroschewski R., Textor M. The study of polarisation in single cells using model cell membranes. Integr. Biol. 2012, 4:1059-1071.
52. Li L., Fukunaga-Kalabis M., Herlyn M. The three-dimensional human skin reconstruct model: a tool to study normal skin and melanoma progression. J. Vis. Exp. 2011, 3. e2937.
53. Lee G.Y., Kenny P.A., Lee E.H., Bissell M.J. Three-dimensional culture models of normal and malignant breast epithelial cells. Nat. Methods 2007, 4:359-365.
54. Hirschhaeuser F., Menne H., Dittfeld C., West J., Mueller-Klieser W., Kunz-Schughart L.A. Multicellular tumor spheroids: an underestimated tool is catching up again. J. Biotechnol. 2010, 148:3-15.
55. Liu W.F., Chen C.S. Cellular and multicellular form and function. Adv. Drug Deliv. Rev. 2007, 59:1319-1328.
56. Dusseiller M., Smith M.L., Vogel V., Textor M. Microfabricated three-dimensional environments for single cell studies. Biointerphases 2006, 1:1-4.
57. Charnley M., Anderegg F., Holtackers R., Textor M., Meraldi P. Effect of cell shape and dimensionality on spindle orientation and mitotic timing. PLoS ONE 2013, 8:e66918.
58. Ochsner M., Textor M., Vogel V., Smith M.L. Dimensionality controls cytoskeleton assembly and metabolism of fibroblast cells in response to rigidity and shape. PLoS ONE 2010, 5:e9445.
59. Chen C., Mrksich M., Huang S., Whitesides G., Ingber D.E. Geometric control of cell life and death. Science 1997, 276:1425-1428.
60. Wlodkovic D., Cooper J.M. Tumors on chips: oncology meets microfluidics. Curr. Opin. Chem. Biol. 2010, 14:556-557.
61. Gidrol X., Fouqué B., Ghenim L., Haguet V., Picollet-D'hahan N., Schaack B. 2D and 3D cell microarrays in pharmacology. Curr. Opin. Pharmacol. 2009, 9:664-668.
62. Håkanson M., Kobel S., Lutolf M.P., Textor M., Cukierman E., Charnley M. Controlled breast cancer microarrays for the deconvolution of cellular multilayering and density effects upon drug responses. PLoS ONE 2012, 7:e40141.
63. Kim M.S., Yeon J.H., Park J.-K. A microfluidic platform for 3-dimensional cell culture and cell-based assays. Biomed. Microdevices 2007, 9:25-34.
64. Torisawa Y., Mosadegh B., Bersano-Begey T., Steele J.M., Luker K.E., Luker G.D., Takayama S. Microfluidic platform for chemotaxis in gradients formed by CXCL12 source-sink cells. Integr. Biol. 2010, 2:680-686.
65. Rizvi I., Gurkan U.A., Tasoglu S., Alagic N., Celli J.P., Mensah L.B., Mai Z., Demirci U., Hasan T. Flow induces epithelial-mesenchymal transition, cellular heterogeneity and biomarker modulation in 3D ovarian cancer nodules. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:E1974-E1983.
66. Montanez-Sauri S.I., Sung K.E., Berthier E., Beebe D.J. Enabling screening in 3D microenvironments: probing matrix and stromal effects on the morphology and proliferation of T47D breast carcinoma cells. Integr. Biol. 2013, 5:631-640.
67. Bleicher, Bohm H., Muller K., Alanine A. Hit and lead generation: Beyond high-throughput screening. Nat. Rev. Drug Discov. 2003, 2:369-378.
68. Landro J.A. HTS in the new millennium: the role of pharmacology and flexibility. J. Pharmacol. Toxicol. Methods 2000, 44:273-289.
69. Roberge M. Cell-based screen for antimitotic agents and identification of analogues of rhizoxin, eleutherobin and paclitaxel in natural extracts. Cancer Res. 2000, 60:5052-5058.
70. Balis F. Evolution of anticancer drug discovery and the role of cell-based screening box. J. Natl. Cancer Inst. 2002, 85.
71. Denys H., Braems G., Lambein K., Pauwels P., Hendrix A., De Boeck A., Mathieu V., Bracke M., De Wever O. The extracellular matrix regulates cancer progression and therapy response: implications for prognosis and treatment. Curr. Pharm. Des. 2009, 15:1373-1384.
72. Joyce J., Pollard J. Microenvironmental regulation of metastasis. Nat. Rev. Cancer 2009, 9:239-252.
73. Bissell M.J., Radisky D.C., Rizki A., Weaver V.M., Petersen O.W. The organizing principle: microenvironmental influences in the normal and malignant breast. Differentiation 2002, 70:537-546.
74. Sonnenschein C., Soto A.M. The death of the cancer cell. Cancer Res. 2011, 71:4334-4337.
75. Hofmeister V., Schrama D., Becker J.C. Anti-cancer therapies targeting the tumor stroma. Cancer Immunol. Immunother. 2008, 57:1-17.
76. Erkan M., Michalski C.W., Rieder S., Reiser-Erkan C., Abiatari I., Kolb A., Giese N.A., Esposito I., Friess H., Kleeff J. The activated stroma index is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma. Clin. Gastroenterol. Hepatol. 2008, 6:1155-1161.
77. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889, 133:571-573.
78. Langhans T. Pulsirende cavernoese Geschwulst der Miltz mit metastatischen Knoten in der Leber. Virchows Arch. 1879, 75:273-291.
79. Kumar S., Weaver V.M. Mechanics, malignancy, and metastasis: the force journey of a tumor cell. Cancer Metastasis Rev. 2009, 28:113-127.
80. Beacham D.A., Cukierman E. Stromagenesis: the changing face of fibroblastic microenvironments during tumor progression. Semin. Cancer Biol. 2005, 15:329-341.
81. Cook L.M., Hurst D.R., Welch D.R. Metastasis suppressors and the tumor microenvironment. Semin. Cancer Biol. 2011, 21:113-122.
82. Witz I.P., Levy-Nissenbaum O. The tumor microenvironment in the post-PAGET era. Cancer Lett. 2006, 242:1-10.
83. Tarin D. Clinical and biological implications of the tumor microenvironment. Cancer Microenviron. 2012, 5:95-112.
84. Rønnov-Jessen L., Bissell M. Breast cancer by proxy: can the microenvironment be both the cause and consequence?. Trends Mol. Med. 2008, 15:5-13.
85. Kunz-Schughart L.A., Knuechel R. Tumor associated fibroblasts (Part II): functional impact on tumor tissue. Histol. Histopathol. 2002, 2:623-637.
86. Conklin M.W., Eickhoff J.C., Riching K.M., Pehlke C.A., Eliceiri K.W., Provenzano P.P., Friedl A., Keely P.J. Aligned collagen is a prognostic signature for survival in human breast carcinoma. Am. J. Pathol. 2011, 178:1221-1232.
87. Amatangelo M.D., Bassi D.E., Klein-Szanto A.J., Cukierman E. Stroma-derived three-dimensional matrices are necessary and sufficient to promote desmoplastic differentiation of normal fibroblasts. Am. J. Pathol. 2005, 167:475-488.
88. Levental K.R., Yu H., Kass L., Lakins J.N., Egeblad M., Erler J.T., Fong S.F.T., Csiszar K., Giaccia A., Weninger W., Yamauchi M., Gasser D.L., Weaver V.M. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 2009, 139:891-906.
89. Bissell M., LaBarge M. Context, tissue plasticity, and cancer: are tumor stem cells also regulated by the microenvironment?. Cancer Cell 2005, 7:17-23.
90. Polanska U.M., Orimo A. Carcinoma-associated fibroblasts: non-neoplastic tumour-promoting mesenchymal cells. J. Cell. Physiol. 2013, 228:1651-1657.
91. Castelló-Cros R., Cukierman E. Stromagenesis during tumorigenesis: characterization of tumor-associated fibroblasts and stroma-derived 3D matrices. Methods Mol. Biol. 2009, 522:275-305.
92. Mehner C., Radisky D.C. Triggering the landslide: the tumor-promotional effects of myofibroblasts. Exp. Cell Res. 2013, 319:1657-1662.
93. Lu P., Weaver V.M., Werb Z. The extracellular matrix: a dynamic niche in cancer progression. J. Cell Biol. 2012, 196:395-406.
94. Oskarsson T., Massague J. Extracellular matrix players in metastatic niches. EMBO J. 2012, 31:254-256.
95. Otranto M., Sarrazy V., Bonté F., Hinz B., Gabbiani G., Desmouliere A. The role of the myofibroblast in tumor stroma remodeling. Cell Adhes. Migr. 2012, 6:203-219.
96. Shields M.A., Dangi-Garimella S., Redig A.J., Munshi H.G. Biochemical role of the collagen-rich tumour microenvironment in pancreatic cancer progression. Biochem. J. 2012, 441:541-552.
97. Strell C., Rundqvist H., Östman A. Fibroblasts-a key host cell type in tumor initiation, progression, and metastasis. Ups. J. Med. Sci. 2012, 117:187-195.
98. Wittekind C., Neid M. Cancer invasion and metastasis. Oncology 2005, 69:14-16.
99. Jodele S., Blavier L., Yoon J.M., DeClerck Y.A. Modifying the soil to affect the seed: role of stromal-derived matrix metalloproteinases in cancer progression. Cancer Metastasis Rev. 2006, 25:35-43.
100. Ronnov-Jessen L., Petersen O., Bissell M.J. Cellular changes involved in conversion of normal to malignant breast: importance of the stromal reaction. Physiol. Rev. 1996, 76:69-125.
101. Paraiso K.H.T., Smalley K.S.M. Fibroblast-mediated drug resistance in cancer. Biochem. Pharmacol. 2013, 85:1033-1041.
102. Minchinton A., Tannock I.F. Drug penetration in solid tumors. Nat. Rev. Cancer 2006, 6:583-592.
103. St Croix B., Sheehan C., Rak J.W., Flørenes V.A., Slingerland J.M., Kerbel R.S. E-Cadherin-dependent growth suppression is mediated by the cyclin-dependent kinase inhibitor p27(KIP1). J. Cell Biol. 1998, 142:557-571.
104. Hazlehurst L.A., Landowski T.H., Dalton W.S. Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell death. Oncogene 2003, 22:7396-7402.
105. Aoudjit F., Vuori K. Integrin signaling in cancer cell survival and chemoresistance. Chemother. Res. Pract. 2012, 2012:16.
106. Quiros R.M., Valianou M., Kwon Y., Brown K.M., Godwin A.K., Cukierman E. Ovarian normal and tumor-associated fibroblasts retain in vivo stromal characteristics in a 3-D matrix-dependent manner. Gynecol. Oncol. 2008, 110:99-109.
107. Sherman-Baust C., Weeraratna A., Rangel L., Pizer E., Cho K., Schwartz D., Schock T., Morin P. Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells. Cancer Cell 2003, 3:377-386.
108. Lito P., Pratilas Christine A., Joseph Eric W., Tadi M., Halilovic E., Zubrowski M., Huang A., Wong Wai L., Callahan Margaret K., Merghoub T., Wolchok Jedd D., de Stanchina E., Chandarlapaty S., Poulikakos Poulikos I., Fagin James A., Rosen N. Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell 2012, 22:668-682.
109. Seo B.R., DelNero P., Fischbach C. In vitro models of tumor vessels and matrix: Engineering approaches to investigate transport limitations and drug delivery in cancer. Adv. Drug Deliv. Rev. 2014, 69-70:205-216. (this issue).
110. Fang J., Nakamura H., Maeda H. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv. Drug Deliv. Rev. 2011, 63:136-151.
111. Brannon-Peppas L., Blanchette J.O. Nanoparticle and targeted systems for cancer therapy. Adv. Drug Deliv. Rev. 2012, 64:206-212. (Supplement).
112. Polyak D., Eldar-Boock A., Baabur-Cohen H., Satchi-Fainaro R. Polymer conjugates for focal and targeted delivery of drugs. Polym. Adv. Technol. 2013, 24:777-790.
113. Steichen S.D., Caldorera-Moore M., Peppas N.A. A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics. Eur. J. Pharm. Sci. 2013, 48:416-427.
114. Adams G.P., Weiner L.M. Monoclonal antibody therapy of cancer. Nat. Biotechnol. 2005, 23:1147-1157.
115. Boder E.T., Jiang W. Engineering antibodies for cancer therapy. Annu Rev Chem Biomol Eng 2011, vol. 2:53-75. J.M. Prausnitz (Ed.).
116. Byrne J.D., Betancourt T., Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv. Drug Deliv. Rev. 2008, 60:1615-1626.
117. Morgan J.P., Delnero P.F., Zheng Y., Verbridge S.S., Chen J., Craven M., Choi N.W., Diaz-Santana A., Kermani P., Hempstead B., Lopez J.A., Corso T.N., Fischbach C., Stroock A.D. Formation of microvascular networks in vitro. Nat. Protoc. 2013, 8:1820-1836.
118. Verbridge S.S., Chakrabarti A., Delnero P., Kwee B., Varner J.D., Stroock A.D., Fischbach C. Physicochemical regulation of endothelial sprouting in a 3D microfluidic angiogenesis model. J. Biomed. Mater. Res. A 2013, 101:2948-2956.
119. Heller E., Hurchla M.A., Xiang J., Su X., Chen S., Schneider J., Joeng K.-S., Vidal M., Goldberg L., Deng H., Hornick M.C., Prior J.L., Piwnica-Worms D., Long F., Cagan R., Weilbaecher K.N. Hedgehog signaling inhibition blocks growth of resistant tumors through effects on tumor microenvironment. Cancer Res. 2012, 72:897-907.
120. Hehlgans S., Haase M., Cordes N. Signalling via integrins: implications for cell survival and anticancer strategies. BBA Rev. Cancer 2007, 1775:163-180.
121. Hazlehurst L.A., Argilagos R.F., Dalton W.S. β1 integrin mediated adhesion increases Bim protein degradation and contributes to drug resistance in leukaemia cells. Br. J. Haematol. 2007, 136:269-275.
122. Lwin T., Hazlehurst L., Dessureault S., Lai R., Bai W., Sotomayor E., Moscinski L.C., Dalton W.S., Tao J.G. Cell adhesion induces p27Kip1-associated cell-cycle arrest through down-regulation of the SCFSkp2 ubiquitin ligase pathway in mantle-cell and other non-Hodgkin B-cell lymphomas. Blood 2007, 110:1631-1638.
123. Yao E., Zhang H., Chen Y., Lee B., Chew K., Res Cancer Increased beta1 integrin is associated with decreased survival in invasive breast cancer. Cancer Res. 2007, 67:659-664.
124. Park C.C., Zhang H., Pallavicini M., Gray J.W., Baehner F., Park C.J., Bisell M.J. β1 integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three dimensional cultures and in vivo. Cancer Res. 2006, 66:1526-1535.
125. Wang H., Fu W.L., Im J.H., Zhou Z.Y., Santoro S.A., Iyer V., DiPersio C.M., Yu Q.C., Quaranta V., Al-Medhi A., Muschel R.J. Tumor cell α3β1 integrin and vascular laminin-5 mediate pulmonary arrest and metastasis. J. Cell Biol. 2004, 164:935-941.
126. Mori Y., Shimizu N., Dallas M., Niewolna M., Story B., Williams P., Mundy G., Yoneda T. Anti-alpha 4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis. Blood 2004, 104:2149-2154.
127. Manegold C., Vansteenkiste J., Cardenal F., Schuette W., Woll P.J., Ulsperger E., Kerber A., Eckmayr J., von Pawel J. Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer. Invest New Drugs 2013, 31:175-182.
128. Patel S., Jenkins J., Papadopolous N., Burgess M., Plager C., Gutterman J., Benjamin R. Pilot study of vitaxin - an angiogenesis inhibitor - in patients with advanced leiomyosarcomas. Cancer 2001, 92:1347-1348.
129. Delbaldo C., Raymond E., Vera K., Hammershaimb L., Kaucic K., Lozahic S., Marty M., Faivre S. Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors. Invest New Drugs 2008, 26:35-43.
130. Hersey P., Sosman J., O'Day S., Richards J., Bedikian A., Gonzalez R., Sharfman W., Weber R., Logan T., Buzoianu M., Hammershaimb L., Kirkwood J.M., Etaracizumab G. Melanoma study, a randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or-dacarbazine in patients with stage IV metastatic melanoma. Cancer 2010, 116:1526-1534.
131. Moschos S.J., Sander C.A., Wang W., Reppert S.L., Drogowski L.M., Jukic D.M., Rao U.N., Athanassiou C., Buzoianu M., Mandic M., Richman L., McKinney L., Leininger J., Tice D.A., Hammershaimb L., Kirkwood J.M. Pharmacodynamic (phase 0) study using etaracizumab in advanced melanoma. J. Immunother. 2010, 33:316-325.
132. Marlind J., Pisoni I., Neri D. Tumor vascular targeting. Drugs Future 2006, 31:901-913.
133. Hood J., Bednarski M., Frausto R., Guccione S., Reisfeld R., Xiang R., Cheresh D.A. Tumor regression by targeted gene delivery to neovasculature. Science 2002, 296:2404-2407.
134. Ono S., Ishii G., Nagai K., Takuwa T., Yoshida J., Nishimura M., Hishida T., Aokage K., Fujii S., Ikeda N., Ochiai A. Podoplanin-positive cancer-associated fibroblasts could have prognostic value independent of cancer cell phenotype in stage I lung squamous cell carcinoma: usefulness of combining analysis of both cancer cell phenotype and cancer-associated fibroblast phenotype. CHEST J. 2013, 143:963-970.
135. Jia Z., Wang Y., Sawyers A., Yao H., Rahmatpanah F., Xia X.-Q., Xu Q., Pio R., Turan T., Koziol J.A., Goodison S., Carpenter P., Wang-Rodriguez J., Simoneau A., Meyskens F., Sutton M., Lernhardt W., Beach T., Monforte J., McClelland M., Mercola D. Diagnosis of prostate cancer using differentially expressed genes in stroma. Cancer Res. 2011, 71:2476-2487.
136. Niu H., Jiang H., Cheng B., Li X., Dong Q., Shao L., Liu S., Wang X. Stromal proteome expression profile and muscle-invasive bladder cancer research. Cancer Cell Int. 2012, 12:39.
137. Harbeck N., Salem M., Nitz U., Gluz O., Liedtke C. Personalized treatment of early-stage breast cancer: present concepts and future directions. Cancer Treat. Rev. 2010, 36:584-594.
138. Weigelt B., Bissell M.J. The need for complex 3D culture models to unravel novel pathways and identify accurate biomarkers in breast cancer. Adv. Drug Deliv. Rev. 2014, 69-70:42-51. (this issue).
139. Hidalgo M., Bruckheimer E., Rajeshkumar N.V., Garrido-Laguna I., De Oliveira E., Rubio-Viqueira B., Strawn S., Wick M.J., Martell J., Sidransky D. A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol. Cancer Ther. 2011, 10:1311-1316.
140. Underhill G.H., Galie P., Chen C.S., Bhatia S.N. Bioengineering methods for analysis of cells in vitro. Annu. Rev. Cell Dev. Biol. 2012, 28:385-410.
141. Faia-Torres A., Goren T., Textor M., Pla-Roca M. Patterned Biointerfaces, in: Comprehensive Biomaterials 2011, Elsevier.
142. Falconnet D., Csucs G., Grandin H.M., Textor M. Surface engineering approaches to micropattern surfaces for cell-based assays. Biomaterials 2006, 27:3044-3063.
143. Azioune A., Storch M., Bornens M., Théry M., Piel M. Simple and rapid process for single cell micro-patterning. Lab Chip 2009, 9:1640-1642.
144. Kleinman H.K., McGarvey M.L., Hassell J.R., Star V.L., Cannon F.B., Laurie G.W., Martin G.R. Basement membrane complexes with biological activity. Biochemistry 1986, 25:312-318.
145. Sodunke T.R., Turner K.K., Caldwell S.A., McBride K.W., Reginato M.J., Noh H.M. Micropatterns of Matrigel for three-dimensional epithelial cultures. Biomaterials 2007, 28:4006-4016.
146. Nelson C., Inman J., Bissell M. Three-dimensional lithographically defined organotypic tissue arrays for quantitative analysis of morphogenesis and neoplastic progression. Nat. Protoc. 2008, 3:674-678.
147. Ochsner M., Dusseiller M.R., Grandin H.M., Luna-Morris S., Textor M., Vogel V., Smith M.L. Micro-well arrays for 3D shape control and high resolution analysis of single cells. Lab Chip 2007, 7:1074-1077.
148. Lutolf M., Doyonnas R., Havenstrite K., Koleckar K., Blau H.M. Perturbation of single hematopoietic stem cell fates in artificial niches. Integr. Biol. 2009, 1:59-69.
149. Zhao R., Boudou T., Wang W.-G., Chen C.S., Reich D.H. Decoupling cell and matrix mechanics in engineered microtissues using magnetically actuated microcantilevers. Adv. Mater. 2013, 25:1699-1705.
150. Lee M., Kumar R., Sukumaran S., Hogg M., Clark D., Dordick J. Three-dimensional cellular microarray for high-throughput toxicology assays. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:59.
151. Pla-Roca M., Leulmi R.F., Djambazian H., Sundararajan S., Juncker D. Addressable nanowell arrays formed using reversibly sealable hybrid elastomer-metal stencils. Anal. Chem. 2010, 82:3848-3855.
152. Bailey S.N., Sabatini D.M., Stockwell R.N. Microarrays of small molecules embedded in biodegradable polymers for use in mammalian cell-based screens. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:16144-16149.
153. Young E.W.K., Beebe D.J. Fundamentals of microfluidic cell culture in controlled microenvironments. Chem. Soc. Rev. 2010, 39:1036.
154. Pihl J., Sinclair J., Sahlin E., Karlsson M., Petterson F., Olofsson J., Orwar O. Microfluidic gradient-generating device for pharmacological profiling. Anal. Chem. 2005, 77:3897-3903.
155. Wu L.Y., Di Carlo D., Lee L.P. Microfluidic self-assembly of tumor spheroids for anticancer drug discovery. Biomed. Microdevices 2008, 10:197-202.
156. Takayama S., Ostuni E., LeDuc P., Naruse K., Ingber D.E., Whitesides G.M. Subcellular positioning of small molecules. Nature 2001, 411:1016.
157. Gómez-Sjöberg R., Leyrat A.A., Pirone D.M., Chen C.S., Quake S.R. Versatile, fully automated, microfluidic cell culture system. Anal. Chem. 2007, 79:8557-8563.
158. Meyer A.S., Hughes-Alford S.K., Kay J.E., Castillo A., Wells A., Gertler F.B., Lauffenburger D.A. 2D protrusion but not motility predicts growth factor-induced cancer cell migration in 3D collagen. J. Cell Biol. 2012, 197:721-729.
159. Doyle A.D., Wang F.W., Matsumoto K., Yamada K.M. One-dimensional topography underlies three-dimensional fibrillar cell migration. J. Cell Biol. 2009, 184:481-490.
160. Choi N.W., Cabodi M., Held B., Gleghorn J.P., Bonassar L.J., Stroock A.D. Microfluidic scaffolds for tissue engineering. Nat. Mater. 2007, 6:908-915.
161. Lii J., Hsu W.-J., Parsa H., Das A., Rouse R., Sia S.K. Real-time microfluidic system for studying mammalian cells in 3D microenvironments. Anal. Chem. 2008, 80:3640-3647.
162. Haessler U., Teo J.C.M., Foretay D., Renaud P., Swartz M.A. Migration dynamics of breast cancer cells in a tunable 3D interstitial flow chamber. Integr. Biol. 2012, 4:401-409.
163. Irimia D., Charras G., Agrawal N., Mitchison T., Toner M. Polar stimulation and constrained cell migration in microfluidic channels. Lab Chip 2007, 7:1783-1790.
164. Haessler U., Kalinin Y., Swartz M.A., Wu M. An agarose-based microfluidic platform with a gradient buffer for 3D chemotaxis studies. Biomed. Microdevices 2009, 11:827-835.
165. Ng C.P., Pun S.H. A perfusable 3D cell-matrix tissue culture chamber for in situ evaluation of nanoparticle vehicle penetration and transport. Biotechnol. Bioeng. 2008, 99:1490-1501.
166. Walsh C.L., Babin B.M., Kasinskas R.W., Foster J.A., McGarry M.J., Forbes N.S. A multipurpose microfluidic device designed to mimic microenvironment gradients and develop targeted cancer therapeutics. Lab Chip 2009, 9:545-554.
167. Ong S.-M., Zhang C., Toh Y.-C., Kim S.H., Foo H.L., Tan C.H., van Noort D., Park S., Yu H. A gel-free 3D microfluidic cell culture system. Biomaterials 2008, 29:3237-3244.
168. Meyvantsson I., Beebe D.J. Cell culture models in microfluidic systems. Annu Rev Anal Chem (Palo Alto, Calif) 2008, 1:423-449.
169. Meyvantsson I., Warrick J., Hayes S., Skoien A., Beebe D. Automated cell culture in high density tubeless microfluidic device arrays. Lab Chip 2008, 8:717-724.
170. Berthier E., Surfus J., Verbsky J., Huttenlocher A., Beebe D.J. A high-content chemotaxis assay for patient diagnosis. Integr. Biol. 2010, 2:630-638.
171. Reticker-Flynn N.E., Malta D.F.B., Winslow M.M., Lamar J.M., Xu M.J., Underhill G.H., Hynes R.O., Jacks T.E., Bhatia S.N. A combinatorial extracellular matrix platform identifies cell-extracellular matrix interactions that correlate with metastasis. Nat. Commun. 2012, 3:1122.
172. Flaim C.J., Chien S., Bhatia S.N. An extracellular matrix microarray for probing cellular differentiation. Nat. Methods 2005, 2:119-125.
173. Niles A., Moravec R.A., Riss T.L. Update on in vitro cytotoxicity assays for drug development. Expert Opin. Drug Discovery 2008, 3:655-669.
174. Tanaka M., Bateman R., Rauh D., Vaisberg E., Ramachandani S., Zhang C., Hansen K.C., Burlingame A.L., Trautman J.K., Shokat K.M., Adams C.L. An unbiased cell morphology-based screen for new, biologically active small molecules. PLoS Biol. 2005, 3.
175. Lang P., Yeow K., Nichols A., Scheer A. Cellular imaging in drug discovery. Nat. Rev. Drug Discov. 2006, 5:343-356.
176. Lövborg H., Nygren P., Larsson R. Multiparametric evaluation of apoptosis: effects of standard cytotoxic agents and the cyanoguanidine CHS 828. Mol. Cancer Ther. 2004, 3:521-526.
177. Errington R.J., Chappell S.C., Khan I.A., Marquez N., Wiltshire M., Griesdoorn V.D., Smith P.J., et al. Time-Lapse Microscopy Approaches to Track Cell Cycle and Lineage Progression at the Single-Cell Level. Current protocols in cytometry/editorial board 2013, (Chapter 12, Unit12 14). J. Paul Robinson (Ed.).
178. van Roosmalen W., Le Devedec S.E., Zovko S., de Bont H., van de Water B. Functional screening with a live cell imaging-based random cell migration assay. Methods in molecular biology (Clifton, N.J.) 2011, 769:435-448.
179. Dusseiller M., Schlaepfer D., Koch M., Kroschewski R., Textor M. An inverted microcontact printing method on topographically structured polystyrene chips for arrayed micro-3-D culturing of single cells. Biomaterials 2005, 26:5917-5925.
180. Younan X., Whitesides G. Soft lithography. Annu. Rev. Mater. Sci. 1998, 33.
181. Young E.W.K., Berthier E., Guckenberger D.J., Sackmann E., Lamers C., Mayvantsson I., Huttenlocher A., Beebe D.J. Rapid prototyping of arrayed microfluidic systems in polystyrene for cell-based assays. Anal. Chem. 2011, 83:1408-1417.
182. Jeon J.S., Chung S., Kamm R.D., Charest J.L. Hot embossing for fabrication of a microfluidic 3D cell culture platform. Biomed. Microdevices 2011, 13:325-333.
183. Wang Z., Kim M.-C., Marquez M., Thorsen T. High-density microfluidic arrays for cell cytotoxicity analysis. Lab Chip 2007, 7:740.
184. Reif R.D., Martinez M.M., Wang K., Pappas D. Simultaneous cell capture and induction of apoptosis using and anti-CD95 affinity microdevice. Anal. Bioanal. Chem. 2009, 395:787-795.
185. Ye N., Qin J., Shi W., Liu X., Lin B. Cell-based high content screening using an integrated microfluidic device. Lab Chip 2007, 7:1696-1704.
186. Strobl J.S., Nikkhah M., Agah M. Actions of the anti-cancer drug suberoylanilide hydroxamic acid (SAHA) on human breast cancer cytoarchitecture in silicon microstructures. Biomaterials 2010, 31:7043-7050.
187. Schauer K., Duong T., Bleakley K., Bardin S., Bornens M., Goud B. Probabilistic density maps to study global endomembrane organization. Nat. Methods 2010, 7:560-566.
188. Mercey E., Obeid P., Glaise D., Calvo-Munoz M.-L., Guguen-Guillouzo C., Fouque B. The application of 3D micropatterning of agarose substrate for cell culture and in situ comet assays. Biomaterials 2010, 31:3156-3165.
189. Lindstrom S., Andersson-Svahn H. Overview of single-cell analyses: microdevices and applications. Lab Chip 2010, 10:3363-3372.
190. Lautenschläger F., Paschke S., Schinkinger S., Bruel A., Beil M., Guck J. The regulatory role of cell mechanics for migration of differentiating myeloid cells. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:15696-15701.
191. Rolli C.G., Seufferlein T., Kemkemer R., Spatz J. Impact of tumor cell cytoskeleton organization on invasiveness and migration: a microchannel-based approach. PLoS ONE 2010, 5:e8726.
192. Irimia D., Toner M. Spontaneous migration of cancer cells under conditions of mechanical confinement. Integr. Biol. 2009, 1:506-512.
193. Wlodkovic D., Faley S., Zagnoni M., Wikswo J.P., Cooper J.M. Microfluidic single-cell array cytometry for the analysis of tumor apoptosis. Anal. Chem. 2009, 81:5517-5523.
194. Generelli S., Jacquemart R., de Rooij N.F., Jolicoeur M., Koudelka-Hep M., Guenat O.T. Potentiometric platform for the quantification of cellular potassium efflux. Lab Chip 2008, 8:1210-1215.
195. Wolf P., Rothermel A., Beck-Sickinger A.G., Robitzki A.A. Microelectrode chip based real time monitoring of vital MCF-7 mamma carcinoma cells by impedance spectroscopy. Biosens. Bioelectron. 2008, 24:253-259.
196. Nelson C., Chen C. Cell-cell signaling by direct contact increases cell proliferation via a PI3K-dependent signal. FEBS Lett. 2002, 514:238-242.
197. Tan C., Seo B., Brooks D., Chandler E., Craighead H., Fischbach C. Parylene peel-off arrays to probe the role of cell-cell interactions in tumour angiogenesis. Integr. Biol. 2009, 1:587-594.
198. Nelson C.M., Khauv D., Bissell M.J., Radisky D.C. Change in cell shape is required for matrix metalloproteinase-induced epithelial-mesenchymal transition of mammary epithelial cells. J. Cell. Biochem. 2008, 105:25-33.
199. Gomez E.W., Chen Q.K., Gjorevski N., Nelson C.M. Tissue geometry patterns epithelial-mesenchymal transition via intercellular mechanotransduction. J. Cell. Biochem. 2010, 110:44-51.
200. Théry M., Racine V., Pepin A., Piel M., Chen Y., Sibarta J.-B., Bornens M. The extracellular matrix guides the orientation of the cell division axis. Nat. Cell Biol. 2005, 7:947-953.
201. Tseng Q., Wang I., Duchemin-Pelletier E., Azioune A., Carpi N., Gao J., Filhol O., Piel M., Thery M., Balland M. A new micropatterning method of soft substrates reveals that different tumorigenic signals can promote or reduce cell contraction levels. Lab Chip 2011, 11:2231-2240.
202. Vasiliev J.M., Omelchenko T., Gelfand I.M., Feder H.H., Bonder E.M. Rho overexpression leads to mitosis-associated detachment of cells from epithelial sheets: a link to the mechanism of cancer dissemination. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:12526-12530.
203. Kwon Y., Cukierman E., Godwin A.K. Differential expression of adhesive molecules and proteases define mechanisms of ovarian tumor cell matrix penetration/invasion. PLoS ONE 2011, 6:e18872.
204. Nelson C.M., Vanduijn M.M., Inman J.L., Fletcher D.A., Bissell M.J. Tissue geometry determines sites of mammary branching morphogenesis in organotypic cultures. Science 2006, 314:298-300.
205. Daley W.P., Yamada K.M. ECM-modulated cellular dynamics as a driving force for tissue morphogenesis. Curr. Opin. Genet. Dev. 2013, 23:408-414.
206. Charnley M., Textor M., Khademohosseini A., Lutolf M. Integration column: microwell arrays for mammalian cell culture. Integr. Biol. 2009, 1:625-634.
207. den Elzen N., Buttery C.V., Maddugoda M.P., Ren G., Yap A.S. Cadherin adhesion receptors orient the mitotic spindle during symmetric cell division in mammalian epithelia. Mol. Biol. Cell 2009, 20:3740-3750.
208. Tsai J., Kam L.C. Lateral mobility of E-Cadherin enhances rac1 response in epithelial cells. Cell. Mol. Bioeng. 2010, 3:84-90.
209. Andreasson-Ochsner M., Romano G., Hakanson M., Smith M.L., Leckband D.E., Textor M., Reimhult E. Single cell 3-D platform to study ligand mobility in cell-cell contact. Lab Chip 2011, 11:2876-2883.
210. Dong-Le Bourhis X., Berthois Y., Millot G., Degeorges A., Sylvi M., Martin P.-M., Calvo F. Effect of stromal and epithelial cells derived from normal and tumorous breast tissue on the proliferation of human breast cancer cell lines in co-culture. Int. J. Cancer 1997, 71:42-48.
211. Albrecht D.R., Underhill G.H., Wassermann T.B., Sah R.L., Bhatia S.N. Probing the role of multicellular organization in three-dimensional microenvironments. Nat. Methods 2006, 3:369-375.
212. Huang Y., Agrawal B., Sun D., Kuo J.S., Williams J.C. Microfluidics-based devices: new tools for studying cancer and cancer stem cell migration. Biomicrofluidics 2011, 5:013412.
213. Sarkar S., Bustard B.L., Welter J.F., Baskaran H. Combined experimental and mathematical approach for development of microfabrication-based cancer migration assay. Ann. Biomed. Eng. 2011, 39:2346-2359.
214. Chung S., Sudo R., Mack P.J., Wan C.-R., Vickerman V., Kamm R.D. Cell migration into scaffolds under co-culture conditions in a microfluidic platform. Lab Chip 2009, 9:269-275.
215. Liu W., Li L., Wang X., Ren L., Wang X., Wang J., Tu Q., Huang X., Wang J. An integrated microfluidic system for studying cell-microenvironmental interactions versatilely and dynamically. Lab Chip 2010, 10:1717-1724.
216. Sung K.E., Yang N., Pehlke C., Keely P.J., Eliceiri K.W., Friedl A., Beebe D.J. Transition to invasion in breast cancer: a microfluidic in vitro model enables examination of spatial and temporal effects. Integr. Biol. 2011, 3:439-450.
217. Song J.W., Cavnar S.P., Walker A.C., Luker K.E., Gupta M., Tung Y.-C., Luker G.D., Takayama S. Microfluidic endothelium for studying the intravascular adhesion of metastatic breast cancer cells. PLoS ONE 2009, 4:e5756.
218. Ma H., Zhang M., Qin J. Probing the role of mesenchymal stem cells in salivary gland cancer on biomimetic microdevices. Integr. Biol. 2012, 4:522-530.
219. Zervantonakis I.K., Hughes-Alford S.K., Charest J.L., Condeelis J.S., Gertler F.B., Kamm R.D. Three-dimensional microfluidic model for tumor cell intravasation and endothelial barrier function. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:13515-13520.
220. Sung J.H., Shuler M.L. A micro cell culture analog (mu CCA) with 3-D hydrogel culture of multiple cell lines to assess metabolism-dependent cytotoxicity of anti-cancer drugs. Lab Chip 2009, 9:1385-1394.
221. Imura Y., Sato K., Yoshimura E. Micro total bioassay system for ingested substances: assessment of intestinal absorption, hepatic metabolism and bioactivity. Anal. Chem. 2010, 82:9983-9988.
222. Sung J.H., Esch M.B., Prot J.-M., Long C.J., Smith A., Hickman J.J., Shuler M.L. Microfabricated mammalian organ systems and their integration into models of whole animals and humans. Lab Chip 2013, 13:1201-1212.
223. Sung J.H., Shuler M.L. Microtechnology for mimicking in vivo tissue environment. Ann. Biomed. Eng. 2012, 40:1289-1300.
224. Kuschel C., Steuer H., Maurer A.N., Kanzok B., Stoop R., Angres B. Cell adhesion profiling using extracellular matrix protein microarrays. BioTechniques 2006, 40:523-531.
225. Aoudjit F., Vuori K. Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells. Oncogene 2001, 20:4995-5004.
226. Labarge M.A., Nelson C.M., Villadsen R., Fridriksdottir A., Ruth J.R., Stampfer M.R., Petersen O.W., Bissell M.J. Human mammary progenitor cell fate decisions are products of interactions with combinatorial microenvironments. Integr. Biol. 2009, 1:70.
227. Dancey J.E., Chen H.X. Strategies for optimizing combinations of molecularly targeted anticancer agents. Nat. Rev. Drug Discov. 2006, 5:649-659.
228. Liu M.C., Tai Y.-C. A 3-D microfluidic combinatorial cell array. Biomed. Microdevices 2011, 13:191-201.
229. Menendez J., Ropero S., del Mar Barbacid M., Montero S., Solanas M., Escrich E., Cortes-Funes H., Colomer R. Synergistic interaction between vinorelbine and gamma-linolenic acid in breast cancer cells. Breast Cancer Res. Treat. 2002, 72:203-219.
230. Chang A., Garrow G. Pilot-study of vinorelbine (navelbine) and paclitaxel (taxol) in patients with refractory breast-cancer and lung-cancer. Semin. Oncol. 1995, 22:66-71.
231. Yin Z., Tao S.-C., Cheong R., Zhu H., Levchenko A. An integrated micro-electro-fluidic and protein arraying system for parallel analysis of cell responses to controlled microenvironments. Integr. Biol. 2010, 2:416-423.
232. Kim K.K., Kugler M.C., Wolters P.J., Robillard L., Galvez M.G., Brumwell A.N., Sheppard D., Chapman H.A. Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:13180-13185.
233. Park E.S., Brown A.C., Difeo M.A., Barker T.H., Lu H. Continuously perfused, non-cross-contaminating microfluidic chamber array for studying cellular responses to orthogonal combinations of matrix and soluble signals. Lab Chip 2010, 10:571.
234. Beske O., Goldbard S., Turpin P. The cell card system: a novel approach to assessing compound selectivity for lead prioritization of G-protein-coupled receptors. Comb. Chem. High Throughput Screen. 2005, 8:293-299.
235. Fang C., Wang Y., Vu N.T., Lin W.-Y., Hsieh Y.-T., Rubbi L., Phelps M.E., Mueschen M., Kim Y.-M., Chatziioannou A.F., Tseng H.-R., Graeber T.G. Integrated microfluidic and imaging platform for a kinase activity radioassay to analyze minute patient cancer samples. Cancer Res. 2010, 70:8299-8308.
236. Gerlinger M., Rowan A.J., Horswell S., Larkin J., Endesfelder D., Gronroos E., Martinez P., Matthews N., Stewart A., Tarpey P., Varela I., Phillimore B., Begum S., McDonald N.Q., Butler A., Jones D., Raine K., Latimer C., Santos C.R., Nohadani M., Eklund A.C., Spencer-Dene B., Clark G., Pickering L., Stamp G., Gore M., Szallasi Z., Downward J., Futreal P.A., Swanton C. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 2012, 366:883-892.
237. Gleghorn J.P., Pratt E.D., Denning D., Liu H., Bander N.H., Tagawa S.T., Nanus D.M., Giannakakou P.A., Kirby B.J. Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody. Lab Chip 2010, 10:27-29.
238. Li P., Stratton Z.S., Dao M., Ritz J., Huang T.J. Probing circulating tumor cells in microfluidics. Lab Chip 2013, 13:602-609.
239. Nagrath S., Sequist L., Maheswaran S., Bell D., Irimia D., Ulkus L., Smith M., Kwak E., Digumarthy S., Muzikansky A. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 2007, 450:1235-1239.
240. Stott S.L., Hsu C.-H., Tsukrov D.I., Yu M., Miyamoto D.T., Waltman B.A., Rothenberg S.M., Shah A.M., Smas M.E., Korir G.K., Floyd F.P., Gilman A.J., Lord J.B., Winokur D., Springer S., Irimia D., Nagrath S., Sequist L.V., Lee R.J., Isselbacher K.J., Maheswaran S., Haber D.A., Toner M. Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:18392-18397.
241. Weigum S.E., Floriano P.N., Christodoulides N., McDevitt J.T. Cell-based sensor for analysis of EGFR biomarker expression in oral cancer. Lab Chip 2007, 7:995-1003.
242. Saliba A.E., Saias L., Psychari E., Minc N., Simon D., Bidard F.C., Mathiot C., Pierga J.Y., Fraisier V., Salamero J., Saada V., Farace F., Vielh P., Malaquin L., Viovy J.L. Microfluidic sorting and multimodal typing of cancer cells in self-assembled magnetic arrays. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:14524-14529.
243. Spink B., Cole R., Katz B., Gierthy J., Bradley L., Spink D. Inhibition of MCF-7 breast cancer cell proliferation by MCF-10A breast epithelial cells in coculture. Cell Biol. Int. 2006, 30:227-238.
244. Cukierman E., Pankov R., Yamada K.M. Cell interactions with three-dimensional matrices. Curr. Opin. Cell Biol. 2002, 14:633-640.
245. Moschetta M., Pretto F., Berndt A., Galler K., Richter P., Bassi A., Oliva P., Micotti E., Valbusa G., Schwager K., Kaspar M., Trachsel E., Kosmehl H., Bani M.R., Neri D., Giavazzi R. Paclitaxel enhances therapeutic efficacy of the F8-IL2 immunocytokine to eda-fibronectin-positive metastatic human melanoma xenografts. Cancer Res. 2012, 72:1814-1824.